Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12176281 | 0.89 | ALDH1A1 (0.51) | ALDH1A1LMNAPOLBMEN1KMT2A | |
| SCHEMBL23864554 | 0.83 | ALDH1A1 (0.61) | ALDH1A1LMNAPOLBMEN1KMT2A | |
| SCHEMBL16215680 | 0.83 | ALDH1A1 (0.61) | ALDH1A1LMNAPOLBMEN1KMT2A | |
| SCHEMBL1507019 | 0.83 | HRH3 (0.52) | ALDH1A1MEN1KMT2ASIGMAR1HRH3 | |
| SCHEMBL22254447 | 0.83 | ALDH1A1 (0.53) | ALDH1A1LMNAPOLBMEN1KMT2A | |
| SCHEMBL12160960 | 0.82 | ALDH1A1 (0.54) | ALDH1A1LMNAHRH3MAPK1KDM4E | |
| SCHEMBL7989530 | 0.82 | LMNA (0.83) | ALDH1A1LMNAPOLBMEN1KMT2A | |
| SCHEMBL1045922 | 0.82 | LMNA (0.83) | ALDH1A1LMNAPOLBMEN1KMT2A | |
| SCHEMBL11356824 | 0.82 | LMNA (0.83) | ALDH1A1LMNAPOLBMEN1KMT2A | |
| SCHEMBL7989269 | 0.82 | LMNA (0.83) | ALDH1A1LMNAPOLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4166195-A1 | NOVEL COMPOUND USEFUL AS TOLL-LIKE RECEPTOR 7 ACTIVATION INHIBITOR | Toyama Prefectural University (JP) | 2023-04-19 | — | — | EP | disclosed |
| EP-4015504-A1 | C5AR ANTAGONISTS | ChemoCentryx, Inc. (US) | 2022-06-22 | — | — | EP | disclosed |
| EP-3508477-B1 | C5AR ANTAGONISTS | CHEMOCENTRYX INC (US) | 2021-11-10 | — | — | EP | disclosed |
| EP-3508477-A1 | C5AR ANTAGONISTS | ChemoCentryx, Inc. (US) | 2019-07-10 | — | — | EP | disclosed |
| EP-3078658-B1 | C5AR ANTAGONISTS | CHEMOCENTRYX INC (US) | 2019-04-10 | — | — | EP | disclosed |
| US-20170114017-A1 | C5AR ANTAGONISTS | CHEMOCENTRYX, INC. | 2017-04-27 | — | — | US | disclosed |
| US-20170065604-A1 | C5aR ANTAGONISTS | CHEMOCENTRYX, INC. | 2017-03-09 | — | — | US | disclosed |
| US-9573897-B2 | C5AR antagonists | CHEMOCENTRYX, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| EP-2499146-B1 | TRICYCLIC PYRAZOL AMINE DERIVATIVES | MERCK SERONO SA (CH) | 2016-09-21 | — | — | EP | disclosed |
| US-20160229802-A1 | C5AR ANTAGONISTS | CHEMOCENTRYX, INC. | 2016-08-11 | — | — | US | disclosed |
| US-20150141425-A1 | C5aR ANTAGONISTS | CHEMOCENTRYX, INC. | 2015-05-21 | — | — | US | disclosed |
| US-20150087630-A1 | METHODS OF USE OF DIAZACARBAZOLES FOR TREATING CANCER | GENENTECH, INC. (US) | 2015-03-26 | — | — | US | disclosed |
| US-8906938-B2 | C5aR antagonists | CHEMOCENTRYX, INC. (US) | 2014-12-09 | — | — | US | disclosed |
| US-20130261104-A1 | METHODS OF USE OF DIAZACARBAZOLES FOR TREATING CANCER | GENENTECH, INC. (US) | 2013-10-03 | — | — | US | disclosed |
| US-8501765-B2 | Diazacarbazoles and methods of use | GENENTECH, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-20130172347-A1 | C5AR ANTAGONISTS | CHEMOCENTRYX, INC. | 2013-07-04 | — | — | US | disclosed |
| US-8445515-B2 | C5aR antagonists | CHEMOCENTRYX, INC. (US) | 2013-05-21 | — | — | US | disclosed |
| WO-2011058149-A1 | TRICYCLIC PYRAZOL AMINE DERIVATIVES | MERCK SERONO S.A. (CH) | 2011-05-19 | — | — | WO | disclosed |
| US-20100311753-A1 | C5aR ANTAGONISTS | CHEMOCENTRYX, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100160320-A1 | C5aR ANTAGONISTS | CHEMOCENTRYX, INC. (US) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160320-A1 | C5aR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | ALDH1A1 2966/4885LMNA 2969/4885POLB 3658/4885 |
| US-20150141425-A1 | C5aR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | ALDH1A1 2966/4885LMNA 2969/4885POLB 3658/4885 |
| US-20170114017-A1 | C5AR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | ALDH1A1 2966/4885LMNA 2969/4885POLB 3658/4885 |
| US-20160229802-A1 | C5AR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | ALDH1A1 2966/4885LMNA 2969/4885POLB 3658/4885 |
| US-20100311753-A1 | C5aR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | ALDH1A1 2966/4885LMNA 2969/4885POLB 3658/4885 |
| US-20130172347-A1 | C5AR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | ALDH1A1 2966/4885LMNA 2969/4885POLB 3658/4885 |
| US-20150087630-A1 | METHODS OF USE OF DIAZACARBAZOLES FOR TREATING CANCER | IDH3B, IDH3A, EGLN3 | ALDH1A1 220/4885LMNA 2307/4885POLB 1900/4885 |
| US-20170065604-A1 | C5aR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | ALDH1A1 2882/4885LMNA 2758/4885POLB 3662/4885 |
| US-20130261104-A1 | METHODS OF USE OF DIAZACARBAZOLES FOR TREATING CANCER | IDH3B, IDH3A, EGLN3 | ALDH1A1 220/4885LMNA 2307/4885POLB 1900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.